Back to results
US 2021/0070852 A1Published application
Anti-IL-23p19 Antibody Formulations
AssigneeBoehringer Ingelheim International GmbH
InventorsPatrick Garidel, Torsten SCHULTZ-FADEMRECHT
Life of this patent
Estimating the term…
Abstract
The present disclosure inter alia provides a liquid pharmaceutical formulation comprising a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO: 1 and a heavy chain amino acid sequence according to SEQ ID NO: 2; b) a polyol; and c) a surfactant. The disclosed high concentration formulations are advantageously storage stable and suitable for subcutaneous administration.
Claims77
A liquid pharmaceutical formulation comprising
- a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO:
- 1 and a heavy chain amino acid sequence according to SEQ ID NO:
- 2;
- b) a polyol;
- and
- c) a surfactant.
3 more elements
A stable liquid pharmaceutical formulation comprising
- a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO:
- 1 and a heavy chain amino acid sequence according to SEQ ID NO:
- 2;
- b) a tonicity modifier;
- and
- c) a surfactant,
- wherein the formulation has a pH of 5.5-5.9 and the formulation is isotonic.
4 more elements
Dependencies are inferred from the claim text.